Videos

Durvalumab Plus Tremelimumab Added to Frontline Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Results From a Phase 2 Study

03/30/2023

Jung-Yun Lee, MD, Yonsei University College of Medicine, Korea, discusses the final primary analysis from a phase 2 study that explored durvalumab plus tremelimumab added to frontline neoadjuvant chemotherapy for patients with advanced ovarian cancer.

The findings from this analysis demonstrate the clinical activity and manageable safety profile of this regimen in newly-diagnosed advanced ovarian cancer.

Dr Lee presented these findings at the 2023 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.

Source:

Lee JY, Park J, Lim MC, et al. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer. Presented at 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, FL.

Recent News

News

Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma

11/19/2024

Stephanie Holland ;

Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...

Subset analysis results from the...

11/19/2024

Oncology

News

Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/19/2024

Stephanie Holland ;

Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.

Results from the phase 3...

11/19/2024

Oncology

News

Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.

According to a phase 2 trial,...

11/19/2024

Oncology

News

Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.

According to a randomized...

11/19/2024

Oncology

News

UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer

11/19/2024

Stephanie Holland ;

According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...

According to results from the...

11/19/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology